InvestorsHub Logo
Followers 65
Posts 23968
Boards Moderated 0
Alias Born 11/23/2016

Re: bas2020 post# 400931

Wednesday, 02/01/2023 11:31:55 AM

Wednesday, February 01, 2023 11:31:55 AM

Post# of 463431
That's what the subgroup analysis of the P2a and the P2b/3 trials are for in AD, also supported by the PDD data.

If one is trying to achieve approval based on a biomarker or genotype, then it is imperative to also include patients who do not exhibit the biomarker or genotype in order to substantiate proof.


Sound like you have lost the plot a bit here and don't quite get the whole Precision Medicine thing.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News